Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
KRAS G12V
|
colorectal cancer
|
resistant |
|
Cetuximab
|
Preclinical |
Actionable |
In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).
|
25838391
|
KRAS G12V
|
pancreatic ductal adenocarcinoma
|
decreased response |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Selumetinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, pancreatic ductal adenocarcinoma cells harboring KRAS G12V demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture when compared to the combined therapy of Selumetinib (AZD6244) and SHP099 (PMID: 30045908).
|
30045908
|
KRAS G12V
|
lung cancer
|
sensitive |
|
7RH + LY411575
|
Preclinical |
Actionable |
In a preclinical study, 7RH and LY411575 combination treatment resulted in additive effect on apoptosis in KRAS G12V-driven animal models of lung cancer (PMID: 26855149).
|
26855149
|
KRAS G12V
|
pancreatic ductal adenocarcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
GS-493 + Selumetinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, GS-493 and Selumetinib (AZD6244) synergistically inhibited growth of pancreatic ductal adenocarcinoma cells harboring KRAS G12V in culture (PMID: 29808009).
|
29808009
|
KRAS G12V
|
colorectal cancer
|
sensitive |
AZD4785
|
AZD4785
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of colorectal cancer cell lines harboring KRAS G12V (PMID: 28615361).
|
28615361
|
KRAS G12V
|
colon cancer
|
sensitive |
|
AZ-TAK1
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a colon cancer cell line harboring KRAS G12V demonstrated sensitivity to AZ-TAK1 in culture, resulting in inhibition of cell growth (PMID: 27655129).
|
27655129
|
KRAS G12V
|
pancreatic ductal adenocarcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, GS-493 and Mekinist (trametinib) synergistically inhibited growth of pancreatic ductal adenocarcinoma cells harboring KRAS G12V in culture (PMID: 29808009).
|
29808009
|
KRAS G12V
|
lung cancer
|
predicted - sensitive |
|
RMC-4550
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, RMC-4550 inhibited growth in 2 of 3 lung cancer cell lines harboring KRAS G12V in 3D culture (PMID: 30104724).
|
30104724
|
KRAS G12V
|
lung small cell carcinoma
|
predicted - resistant |
|
RMC-4550
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, RMC-4550 did not inhibit growth of lung small cell cancer cells harboring KRAS G12V in 3D culture (PMID: 30104724).
|
30104724
|
KRAS G12V
|
head and neck squamous cell carcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Sirolimus + Trametinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines overexpressing KRAS G12V in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).
|
26882569
|
KRAS G12V
|
Advanced Solid Tumor
|
predicted - sensitive |
|
PF3644022 + PF-477736
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing KRAS G12V in culture, while single agent inhibition had no effect (PMID: 26140595).
|
26140595
|
KRAS G12V
|
colorectal cancer
|
sensitive |
|
Regorafenib + Cetuximab
|
Preclinical |
Actionable |
In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G12V in culture (PMID: 25838391).
|
25838391
|
KRAS G12V
|
colorectal cancer
|
sensitive |
PIK3CA inhibitor
|
Alpelisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 27602501).
|
27602501
|
KRAS G12V
|
colorectal cancer
|
resistant |
|
Regorafenib
|
Preclinical |
Actionable |
In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
|
25838391
|
KRAS G12V
|
colorectal cancer
|
sensitive |
|
Oxaliplatin
|
Preclinical |
Actionable |
In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS G12V (PMID: 23209813).
|
23209813
|
KRAS G12V
|
colorectal cancer
|
sensitive |
RAS Inhibitor (Pan)
|
3144
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, 3144 inhibited growth of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 28235199).
|
28235199
|
KRAS G12V
|
lung adenocarcinoma
|
decreased response |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Selumetinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
|
27422710
|
KRAS G12V
|
non-small cell lung carcinoma
|
predicted - sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Selumetinib + Docetaxel
|
Phase I |
Actionable |
In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448).
|
26125448
|
KRAS G12V
|
lung cancer
|
sensitive |
|
Aurora Kinase Inhibitor II
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Aurora Kinase Inhibitor II (AI II) decreased viability of transformed lung cells expressing KRAS G12V in culture (PMID: 26842935).
|
26842935
|
KRAS G12V
|
ovarian serous carcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Selumetinib
|
Clinical Study |
Actionable |
In a clinical case study, treatment with Selumetinib (AZD6244) resulted in lack of tumor progression for greater than 7 years in patient with low grade serous ovarian carcinoma harboring KRAS G12V (PMID: 27231576).
|
27231576
|
KRAS G12V
|
pancreatic ductal adenocarcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
SHP099 + Trametinib
|
Preclinical - Pdx & cell culture |
Actionable |
In a preclinical study, SHP099 and Mekinist (trametinib) synergistically inhibited growth of pancreatic ductal adenocarcinoma cells harboring KRAS G12V in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models (PMID: 29808009).
|
29808009
|
KRAS G12V
|
pancreatic ductal adenocarcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
SHP099 + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination therapy of Mekinist (trametinib) and SHP099 led to reduced cell viability in pancreatic ductal adenocarcinoma cells harboring KRAS G12V in culture (PMID: 30045908).
|
30045908
|
KRAS G12V
|
colorectal cancer
|
resistant |
|
Sunitinib
|
Preclinical |
Actionable |
In a preclinical study, a colorectal cancer cell line harboring the KRAS G12V mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).
|
23455880
|
KRAS G12V
|
colon cancer
|
sensitive |
|
Luminespib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Luminespib (AUY922) inhibited growth of colon cancer cell lines harboring KRAS G12V in culture (PMID: 26832792).
|
26832792
|
KRAS G12V
|
pancreatic ductal adenocarcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Selumetinib + SHP099
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination therapy of Selumetinib (AZD6244) and SHP099 resulted in a synergistic effect, demonstrating reduced cell proliferation and decreased colony formation in pancreatic ductal adenocarcinoma cells harboring KRAS G12V (PMID: 30045908).
|
30045908
|
KRAS G12V
|
colon cancer
|
predicted - resistant |
|
RMC-4550
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, RMC-4550 did not inhibit growth of colon cancer cell lines harboring KRAS G12V in 3D culture (PMID: 30104724).
|
30104724
|
KRAS G12V
|
non-small cell lung carcinoma
|
sensitive |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Pimasertib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12V in culture (PMID: 23629727).
|
23629727
|
KRAS G12V
|
pancreatic cancer
|
predicted - resistant |
|
RMC-4550
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, RMC-4550 did not inhibit growth of pancreatic cancer cells harboring KRAS G12V in 3D culture (PMID: 30104724).
|
30104724
|
KRAS G12V
|
lung adenocarcinoma
|
decreased response |
MEK inhibitor (Pan)
MEK1 Inhibitor
MEK2 Inhibitor
|
Binimetinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
|
27422710
|
KRAS G12V
|
colorectal cancer
|
decreased response |
|
Neratinib
|
Preclinical |
Actionable |
In a preclinical study, colorectal cancer cells harboring KRAS G12V were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).
|
26243863
|